Navigation Links
Breast Cancer Rates Lower With Less Hormone Therapy: Study
Date:11/30/2010

TUESDAY, Nov. 30 (HealthDay News) -- Reduced use of hormone replacement therapy (HRT) is linked to declines in rates of invasive breast cancer and ductal carcinoma in situ, the most common form of noninvasive breast cancer, a new study reports.

The University of California, San Francisco, study included nearly 700,000 women, aged 40 to 79, who underwent more than 2 million screening mammography examinations between January 1997 and December 2008.

Women aged 50 to 69 had the highest level of hormone therapy use and also had the largest reduction in invasive breast cancer when they stopped hormone therapy -- from 40 cancers per 10,000 mammograms in 2002 to 31 cancers in 2005, and 35 cancers in 2006, the investigators found.

The study also found a sharp drop in rates of ductal carcinoma in situ in this age group after they stopped using hormone therapy.

A parallel decrease in these types of breast cancer also occurred among women older than 70. However, there was no change in breast cancer rates during the study period among women aged 40 to 49, who were less likely to have been on hormone therapy.

The researchers said their findings suggest that hormone therapy helped promote breast cancer tumor growth.

"We show that the incidence of breast cancer decreases if you take the hormones away. The fact that we're continuing to see a decrease in invasive [breast] cancer means that the effects of stopping the hormones may be long-lasting," senior author Dr. Karla Kerlikowske said in a university news release.

The study was released online in advance of publication in an upcoming print issue of the Journal of Clinical Oncology.

More information

The U.S. National Cancer Institute has more about hormone replacement therapy and cancer.

-- Robert Preidt

SOURCE: University of California, San Francisco, news release, Nov. 29, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Rates Lower With Less Hormone Therapy: Study
(Date:8/18/2017)... , ... August 18, 2017 , ... The Brian Gifford ... northwest Indiana, is campaigning in support of Campagna Academy in a charity drive to ... the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has ...
(Date:8/18/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has released a new ... the mother of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared ... of this historical woman. , “The world bows, kisses the feet of, cries out ...
(Date:8/18/2017)... ... ... Inheritance”: a mystery about saving the family farm. “Dangerous Inheritance” is the creation ... raised on a farm. As Diane wrote this story, she used fond memories ... of ‘neighbors helping neighbors’ have always been a large part of her farming community. ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Kingdom Mandate for ... the Kingdom. “Kingdom Mandate for Kingdom Builders” is the creation of published author, ... moved to Eastern Europe as a missionary in 1983. He spent three decades ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... organizations and considered extremely effective, very effective, or effective by 85% of respondents, ... , NEJM Catalyst Insights Reports are based on surveys of the NEJM Catalyst ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... Ind. , Aug. 7, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that its Board of Directors has ... for the third quarter of 2017. ... be paid on or about October 27, 2017 to stockholders ... 22, 2017.  Future declarations of dividends are subject to approval ...
Breaking Medicine Technology: